(Total Views: 626)
Posted On: 09/24/2021 11:46:28 PM
Post# of 36568
Recalling an old press release:
Four companies in China have entered a contract with Generex Biotechnology for the development of an Ii-Key Peptide-based Covid-19 vaccine.
The Chinese partners comprise China Technology Exchange, Beijing Zhonghua Investment Fund Management, Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen).
I just saw this:
Meng Jin
Affiliation：
Key Laboratory for Drug Screening Technology,
Biology Institute of Shandong Academy of Sciences
Funding (year, title, source, amount, role)
“2. Research and development of a novel Ii-key peptide vaccine based on the Key antigen epitopes of coronavirus (National Program for The Introduction of High-end Foreign Experts by the Ministry of Science and Technology of China, 2020.01-2021.01, 500000 RMB, PI)”
FWIW. Her role was Principal Investigator of whatever was researched.
http://www.drugscreen.org.cn/en/team/20200925/347.html
Four companies in China have entered a contract with Generex Biotechnology for the development of an Ii-Key Peptide-based Covid-19 vaccine.
The Chinese partners comprise China Technology Exchange, Beijing Zhonghua Investment Fund Management, Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen).
I just saw this:
Meng Jin
Affiliation：
Key Laboratory for Drug Screening Technology,
Biology Institute of Shandong Academy of Sciences
Funding (year, title, source, amount, role)
“2. Research and development of a novel Ii-key peptide vaccine based on the Key antigen epitopes of coronavirus (National Program for The Introduction of High-end Foreign Experts by the Ministry of Science and Technology of China, 2020.01-2021.01, 500000 RMB, PI)”
FWIW. Her role was Principal Investigator of whatever was researched.
http://www.drugscreen.org.cn/en/team/20200925/347.html
(6)
(0)
